HALO logo
halo search icon
Arvinas, Inc.

US$9.10

Price Change Indicator
0.55 (6.43%)
Arvinas, Inc.
ARVN · NAS

Arvinas, Inc.

Start Trading ARVN for Free

US$9.10

Price Arrow0.55 (6.43%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusEMA 125 BreakdownFakey Shakey - LongFakey Shakey - Long (Realtime)HALO AllHALO Earnings MomentumNear Support
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Arvinas, Inc. Overview

ARVN Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ARVN

icon
icon

Telephone

1.203.535.1456

icon

Address

395 Winchester Avenue, 5 Science Park, New Haven, CT 06511

Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

ARVN Price Chart

Key Stats

Market Cap

US$551.66M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 6.05 - 14.51

Trade Value (12mth)

US$3,738,030.00

1 week

-5.84%

1 month

-19.49%

YTD

-25.46%

1 year

36.8%

All time high

108.46

Key Fundamentals

EPS 3 yr Growth

-78.50%

EBITDA Margin

-41.80%

Operating Cashflow

-$274m

Free Cash Flow Return

-54.20%

ROIC

-16.00%

Interest Coverage

0.00

Quick Ratio

4.90

Other Data

Shares Outstanding (Fully Diluted)

64m

HALO Sector

Healthcare

Next Company Report Date

01-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

ARVN Announcements

Latest Announcements

DateAnnouncements
12 May 26
12 May 26
12 May 26
12 May 26
12 May 26

ARVN Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-6.62-2.77-1.14locklocklock
EPS (Fully Diluted)
 $locklocklocklock-6.62-2.77-1.14locklocklock
Growth
 %locklocklocklock-24.658.258.8locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Arvinas, Inc. (ARVN:NAS)?
Halo FAQ
The current share price of Arvinas, Inc. (ARVN:NAS) is USD$9.10.
What is the 52-week high share price for Arvinas, Inc. (ARVN:NAS)?
Halo FAQ
The 52-week high share price for Arvinas, Inc. (ARVN:NAS) is USD$14.51.
What is the 52-week low share price for Arvinas, Inc. (ARVN:NAS)?
Halo FAQ
The 52-week low share price for Arvinas, Inc. (ARVN:NAS) is USD$6.05.
What is the dividend yield for Arvinas, Inc. (ARVN:NAS)?
Halo FAQ
Arvinas, Inc. (ARVN:NAS) does not pay a dividend.
What was Arvinas, Inc. (ARVN:NAS) last dividend payment?
Halo FAQ
Arvinas, Inc. (ARVN:NAS) does not pay a dividend.
What is the franking level for Arvinas, Inc. (ARVN:NAS)?
Halo FAQ
Arvinas, Inc. (ARVN:NAS) has a franking level of 0.00%.
In which sector is Arvinas, Inc. (ARVN:NAS) classified?
Halo FAQ
Arvinas, Inc. (ARVN:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial